NDA 212161 · Foldrx Pharms
Vyndamax
Tafamidis · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
May 3, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
7 Phase 3, 2 recruiting
FAERS reports
12,176
9,441 serious, 4,214 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2026.
1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )
Mechanism: Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VYNDAMAX · TAFAMIDIS 61MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tafamidis" as an intervention, any sponsor and status, largest first.
- Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02791230 · 1,733 participants · Start Jun 13, 2016 · Primary completion Oct 26, 2023
Drug: Tafamidis · For: Transthyretin (TTR) Amyloid Cardiomyopathy
Sites: Birmingham, Alabama; Beverly Hills, California; La Jolla, California · 80 sites in all
- Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01994889 · 441 participants · Start Dec 9, 2013 · Primary completion Feb 7, 2018
Drug: Tafamidis; Tafamidis and 1 more · For: Transthyretin (TTR) Amyloid Cardiomyopathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 80 sites in all
- Safety and Efficacy Study of Fx-1006A in Patients With Familial AmyloidosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00409175 · 128 participants · Start Jan 2007 · Primary completion May 2009
Drug: Fx-1006A; Placebo · For: Familial Amyloid Polyneuropathy
Sites: Boston, Massachusetts; Ciudad de Buenos Aires, Argentina; Rio de Janeiro, Brazil · 10 sites in all
- Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin AmyloidosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00925002 · 93 participants · Start Aug 5, 2009 · Primary completion Jul 8, 2020
Drug: Tafamidis · For: ATTR-PN
Sites: Baltimore, Maryland; Buenos Aires, Argentina; Rio de Jameiro, Brazil · 9 sites in all
- An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid PolyneuropathyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00791492 · 86 participants · Start Jul 2008 · Primary completion Aug 2008
Drug: Fx-1006A · For: Familial Amyloid Polyneuropathy; ATTR-PN
Sites: Buenos Aires, Argentina; Ciudad de Buenos Aires, Argentina; Rio de Janeiro, Brazil · 11 sites in all
PfizerPfizer (PFE)
NCT04814186 · 53 participants · Start Jul 22, 2021 · Primary completion Oct 16, 2023
Drug: Tafamidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Beijing, China; Wuhan, China; Changsha, China · 9 sites in all
BayerBayer (BAYRY)
NCT07298044 · 50 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 17, 2027
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Sankt Pölten, Austria; Vienna, Austria; Braunau am Inn, Austria · 26 sites in all
PfizerPfizer (PFE)
NCT01775761 · 42 participants · Start Jan 2013 · Primary completion Apr 2013
Drug: Period 1; Period 2 and 1 more · For: TTR Cardiomyopathy
Sites: New Haven, Connecticut; Brussels, Belgium; Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,266
- dyspnoea804
- off label use661
- cardiac failure638
- fatigue585
- fall479
- atrial fibrillation397
- dizziness357
- malaise349
- asthenia332
- condition aggravated311
- cardiac failure congestive308
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 123 |
| 2020 | 644 |
| 2021 | 1,043 |
| 2022 | 1,755 |
| 2023 | 2,500 |
| 2024 | 2,545 |
| 2025 | 2,110 |
| 2026 | 1,447 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyndamax (Tafamidis)
2024 spending
$2.83B
Beneficiaries
13,925
109,373 claims
Per beneficiary
$203,290
$743.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $253,267,541 |
| 2021 | $532,147,190 |
| 2022 | $845,100,487 |
| 2023 | $1,349,659,508 |
| 2024 | $2,830,811,857 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. · Eur J Heart Fail 2022 · Meta-Analysis, Systematic Review
- Hereditary transthyretin-related amyloidosis.
Finsterer J, Iglseder S, Wanschitz J, et al. · Acta Neurol Scand 2019 · Systematic Review
- Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.
Damy T, Wang R, Maurer MS, et al. · Eur J Heart Fail 2025 · Clinical Trial, Phase III, Multicenter Study
- Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Judge DP, Gillmore JD, Alexander KM, et al. · Circulation 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Foldrx Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.